Ramiro Reckziegel

Ramiro Reckziegel

Auto-generated profile, based on publicly available information

Ramiro Reckziegel

Laboratório de Psiquiatria Molecular, Hospital de Clínicas de Porto Alegre, Ramiro Barcelos, 2350, Zip Code: 90035-903, Porto Alegre, Brazil; Programa de Pós-Graduação Em Psiquiatria e Ciências Do Comportamento, Universidade Federal Do Rio Grande Do Sul, Ramiro Barcelos, 2400 - 2° Andar, Zip Code: 90035-003, Porto Alegre, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
JSJuliana M. Sartori
Juliana M. Sartori
RRRamiro Reckziegel
Ramiro Reckziegel
IPIves Cavalcante Passos
Ives Cavalcante Passos
LCLeticia S. Czepielewski
Leticia S. Czepielewski
AFAdam Fijtman
Adam Fijtman
CGClarissa S. Gama
Clarissa S. Gama

1 February 2015 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
LCLetícia S. Czepielewski
Letícia S. Czepielewski
RMRaffael Massuda
Raffael Massuda
PGPedro Goi
Pedro Goi
MSMiréia Sulzbach-Vianna
Miréia Sulzbach-Vianna
RRRamiro Reckziegel
Ramiro Reckziegel
CGClarissa S. Gama
Clarissa S. Gama

1 October 2017 in Schizophrenia Research
Verified
Journal Article
Closed access
JPJairo Vinícius Pinto
Jairo Vinícius Pinto
IPIves Cavalcante Passos
Ives Cavalcante Passos
FGFernando Gomes
Fernando Gomes
RRRamiro Reckziegel
Ramiro Reckziegel
FKFlavio Kapczinski
Flavio Kapczinski
MKMárcia Kauer-Sant'ANna
Márcia Kauer-Sant'ANna

21 February 2013 in Acta Neuropsychiatrica
Verified
Journal Article
Closed access
PDF file
JWJulio C. Walz
Julio C. Walz
PMPedro V. Magalhães
Pedro V. Magalhães
RRRamiro Reckziegel
Ramiro Reckziegel
MCMonise Costanzi
Monise Costanzi
LGLarriany Giglio
Larriany Giglio
FKFlávio Kapczinski
Flávio Kapczinski

5 March 2019 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
MKMárcia Kauer-Sant’aNna
Márcia Kauer-Sant’aNna
BFBenicio Frey
Benicio Frey
AFAdam Fijtman
Adam Fijtman
ALAna C Loredo-Souza
Ana C Loredo-Souza
ADAroldo A Dargél
Aroldo A Dargél
FKFlávio Kapczinski
Flávio Kapczinski
The purpose of this study was to assess the efficacy and tolerability of tianeptine as an adjunctive maintenance treatment for bipolar depression. This is a multicenter double-blind randomized placebo-controlled maintenance trial of adjunctive tianeptine 37.5 mg/day. Participants (n=161) had a Montgomery-Asberg Depression Rating Scale ⩾12 at entry. After eight weeks of open-label tianeptine treatment, those who responded to tianeptine (n=69) were randomized to adjunctive tianeptine (n=36) or placebo (n=33) in addition to usual treatment. Kaplan-Meier estimates and the Mantel-Cox log-rank test were used to evaluate differences in time to intervention for a mood episode between the tianeptine and placebo groups. We also assessed overall functioning, biological rhythms, quality of life, rates of manic switch and serum brain-derived neurotrophic factor levels. There were no differences between adjunctive tianeptine or placebo regarding time to intervention or depression scores in the 24-week double-blind controlled phase. Patients in the tianeptine group showed better performance in the letter-number sequencing subtest from the Wechsler Adult Intelligence Scale at the endpoint (p=0.014). Tianeptine was well tolerated and not associated with higher risk for manic switch compared to placebo. Tianeptine was not more effective than placebo in the maintenance treatment of bipolar depression. There is preliminary evidence suggesting a pro-cognitive effect of tianeptine in working memory compared to placebo.

1 February 2022 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
RRRamiro Reckziegel
Ramiro Reckziegel
LCLetícia S. Czepielewski
Letícia S. Czepielewski
MHMathias Hasse-Sousa
Mathias Hasse-Sousa
DMDayane S. Martins
Dayane S. Martins
MBMaria J. de Britto
Maria J. de Britto
CGClarissa S. Gama
Clarissa S. Gama
The notion that schizophrenia is a neuroprogressive disorder is based on clinical perception of cumulative impairments over time and is supported by neuroimaging and biomarker research. Nevertheless, increasing evidence has indicated that schizophrenia first emerges as a neurodevelopmental disorder that could follow various pathways, some of them neuroprogressive. The objective of this review is to revisit basic research on cognitive processes and neuroimaging findings in a search for candidate keys to the intricate connections between neurodevelopment and neuroprogression in schizophrenia. In the complete panorama, schizophrenia is a neurodevelopmental disorder, possibly associated with an additional burden over the course of the disease through pathologically accelerated aging, and cognitive heterogeneity may explain the different trajectories of each patient.